Mydecine Innovations Group Inc (OTCMKTS: MYCOF) announced MYCO-005 molecules, which belong in the psilocin, could have properties that allow for heart-safe microdoses. In December 2021, the...
Mydecine Innovations Group (OTCMKTS: MYCOF) has announced that in readiness for its pre-IND meeting with the FDA on February 28, 2022, it has submitted a pre-IND...
Mydecine Innovations Group (OTCMKTS: MYCOF) has announced a collaboration with Combat Stress and the King’s College London to use psilocybin in psychoactive-assisted therapy to manage post-traumatic...
Mydecine Innovations Group Inc (OTCMKTS: MYCOF) has recently inked a Letter of Intent (LOI) with Maya. The two have partnered to design and develop a new...
Mydecine Innovations Group (OTCMKTS: MYCOF) has, after a general shareholder meeting, received the consent of its stockholders to arrange the transaction entered into between the company...
Mydecine Innovations Group Inc (OTCMKTS: MYCOF) is back in the news. It is learned that the biopharmaceutical company which works towards developing and introducing solutions for...
Mydecine Innovations Group Inc. (OTCMKTS: MYCOF) has announced its Q2 2021 financial results and offered a business update. The company reported a net loss of $3.8...
